ReviewPharmacology & therapeutics2018
20-HETE in the regulation of vascular and cardiac function.
Review in Pharmacology & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 114 citations in OpenAlex.
- One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial.Arteriosclerosis, thrombosis, and vascular biology · 2024Trial
- Influence of 2 Weeks of Mango Ingestion on Inflammation Resolution after Vigorous Exercise.Nutrients · 2023Trial
- SGLT2 inhibitor ameliorates hypertension by regulating the CYP4A/20-HETE pathway in the kidney.Bioscience reports · 2026Article
- Integrating epidemiological and transcriptomic data reveals novel lipid metabolic drivers of obstructive sleep apnea.Nutrition & metabolism · 2026Article
- Clinical and Biomarker Predictors of Adverse Left Ventricular Remodeling After First STEMI: Insights into Phenotype Variability Using CMR.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Maternal obesity induces macrophage to myofibroblast transition in kidneys of male offspring through a pathway driven by 20-hydroxyeicosatetraenoic acid.Nature communications · 2026Article
- Emerging Roles and Possible Therapeutic Applications of Arachidonic Acid Metabolites in Sepsis and Sepsis-Associated Organ Dysfunction.Drug design, development and therapy · 2026Review
- Comparison of pharmacovigilance and mechanism analysis of the vascular toxicity caused by platin-based chemotherapy: integration of FAERS analysis, network pharmacology, and endothelial validation.Therapeutic advances in drug safety · 2026Article
- Sex-Specific Differences in Rat Renal CYP Enzyme Expression and Activity Following Isoproterenol-Induced Injury.European journal of drug metabolism and pharmacokinetics · 2026Article
- On the interface of fatty acid metabolism: A crosstalk between fatty acid ω-hydroxylase CYP4F11 and fatty acid desaturase 2 in non-small cell lung cancer.Drug metabolism and disposition: the biological fate of chemicals · 2026Article
- Comprehensive Analysis of Different Subtypes of Oxylipins to Determine a LC-MS/MS Approach in Clinical Research.Metabolites · 2025Article
- Retinal Neurovascular Coupling: From Mechanisms to a Diagnostic Window into Brain Disorders.Cells · 2025Review
- Simvastatin inhibits 20-Hydroxyeicosatetraenoic acid formation: docking and in vitro assay.BMC pharmacology & toxicology · 2025Article
- Prospects and Challenges of Catechins in Cardiovascular Disease.The AAPS journal · 2025Review
- The Cytochrome CYP4 in Breast and Other Cancers.Biology · 2025Review
- Endocannabinoid Tone and Oxylipins in Rheumatoid Arthritis and Osteoarthritis-A Novel Target for the Treatment of Pain and Inflammation?International journal of molecular sciences · 2025Article
- Differential Gene and Protein Expressions Responsible for Vasomotor Signaling Provide Mechanistic Bases for the Opposite Flow-Induced Responses of Pre- and Post-Circle of Willis Arteries.Life (Basel, Switzerland) · 2025Article
- Sex-dependent alterations in cardiac cytochrome P450-mediated arachidonic acid metabolism in pressure overload-induced cardiac hypertrophy in rats.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Article
- 20-HETE mediates Ang II-induced cardiac hypertrophy via ROS and CaScientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
20-HETE, the ω-hydroxylation product of arachidonic acid catalyzed by enzymes of the cytochrome P450 (CYP) 4A and 4F gene families, is a bioactive lipid mediator with potent effects on the vasculature including stimulation of smooth muscle cell contractility, migration and proliferation as well as activation of endothelial cell dysfunction and inflammation. Clinical studies have shown elevated levels of plasma and urinary 20-HETE in human diseases and conditions such as hypertension, obesity and metabolic syndrome, myocardial infarction, stroke, and chronic kidney diseases. Studies of polymorphic associations also suggest an important role for 20-HETE in hypertension, stroke and myocardial infarction. Animal models of increased 20-HETE production are hypertensive and are more susceptible to cardiovascular injury. The current review summarizes recent findings that focus on the role of 20-HETE in the regulation of vascular and cardiac function and its contribution to the pathology of vascular and cardiac diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.